To help us meet this need, we are thrilled to be welcoming Rob Quinn to the BenevolentAI team as our new Chief Finance Officer from January 2021. He will take overall responsibility for the Finance Organisation, with a focus on investor relations, fundraising, revenue opportunities and realising our long term growth plans.
Rob brings with him a wealth of scientific and financial experience, having served at GSK as Area Finance Director for Africa & Developing Countries, and as CFO of Silence Therapeutics plc, where he led their listing on Nasdaq. He obtained a PhD in Biochemistry from the University of Manchester and qualified as a Chartered Accountant at Deloitte, where he spent time working in corporate finance advisory within the life sciences sector.
"I am excited to be joining BenevolentAI as Chief Financial Officer” Rob commented, “Benevolent is a business with huge potential and big ambitions to transform the lives of patients, and I look forward to playing my part".
Under Rob’s financial guidance, we will confidently continue to move towards greater levels of innovation by investing in building richer and better technology that will help uncover vital new treatments.
